Clinical trial
Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea
NCT06905288 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 2, 2025
- Completion date
- December 31, 2026
- Enrollment
- 70 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
ankylosing spondylitis